Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.61−0.70 (-4.89%)
Close on Nov 13, 2026Market cap $200.42MP/E –Yield –
Korro Bio total assets
Total assets on the balance sheet at the end of each period.
Korro Bio's total assets was $148.12M at Sep 30, 2026. For fiscal 2025 it was $113.51M, down 49.8% from the year before. The highest annual figure on record is $264.72M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.51M | -49.8% |
| FY2024 | Dec 31, 2024 | $226.24M | +2.1% |
| FY2023 | Dec 31, 2023 | $221.66M | +200.6% |
| FY2022 | Dec 31, 2022 | $73.74M | -60.2% |
| FY2021 | Dec 31, 2021 | $185.36M | -30.0% |
| FY2020 | Dec 31, 2020 | $264.72M | +18.6% |
| FY2019 | Dec 31, 2019 | $223.22M | +401.1% |
| FY2018 | Dec 31, 2018 | $44.55M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $148.12M | -8.3% |
| Q2 FY2026 | Jun 30, 2026 | $163.45M | -9.4% |
| Q1 FY2026 | Mar 31, 2026 | $183.62M | -9.2% |
| Q4 FY2025 | Dec 31, 2025 | $113.51M | -49.8% |
| Q3 FY2025 | Sep 30, 2025 | $161.55M | -33.7% |
| Q2 FY2025 | Jun 30, 2025 | $180.43M | -27.7% |
| Q1 FY2025 | Mar 31, 2025 | $202.21M | +2.1% |
| Q4 FY2024 | Dec 31, 2024 | $226.24M | +2.1% |
| Q3 FY2024 | Sep 30, 2024 | $243.54M | +425.5% |
| Q2 FY2024 | Jun 30, 2024 | $249.59M | +214.4% |
| Q1 FY2024 | Mar 31, 2024 | $197.99M | +95.1% |
| Q4 FY2023 | Dec 31, 2023 | $221.66M | +200.6% |
| Q3 FY2023 | Sep 30, 2023 | $46.35M | -65.9% |
| Q2 FY2023 | Jun 30, 2023 | $79.38M | -47.0% |
| Q1 FY2023 | Mar 31, 2023 | $101.50M | -38.5% |
| Q4 FY2022 | Dec 31, 2022 | $73.74M | -60.2% |
| Q3 FY2022 | Sep 30, 2022 | $136.01M | -32.7% |
| Q2 FY2022 | Jun 30, 2022 | $149.66M | -32.0% |
| Q1 FY2022 | Mar 31, 2022 | $164.94M | -31.7% |
| Q4 FY2021 | Dec 31, 2021 | $185.36M | -30.0% |
| Q3 FY2021 | Sep 30, 2021 | $202.19M | -13.7% |
| Q2 FY2021 | Jun 30, 2021 | $220.21M | +7.5% |
| Q1 FY2021 | Mar 31, 2021 | $241.51M | +12.0% |
| Q4 FY2020 | Dec 31, 2020 | $264.72M | +18.6% |
| Q3 FY2020 | Sep 30, 2020 | $234.32M | +37.2% |
| Q2 FY2020 | Jun 30, 2020 | $204.79M | +359.7% |
| Q1 FY2020 | Mar 31, 2020 | $215.72M | – |
| Q4 FY2019 | Dec 31, 2019 | $223.22M | – |
| Q3 FY2019 | Sep 30, 2019 | $170.85M | – |
| Q4 FY2018 | Dec 31, 2018 | $44.55M | – |
See a number that looks wrong?